A Study to Evaluate the Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients


About this study

The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals will be identified from within the adult allogeneic BMT program at Mayo Clinic in Rochester, Minnesota.
  • Participants must be prescribed tacrolimus for treatment or prevention of GVHD.

Exclusion Criteria:

  • Vulnerable populations.
  • Those lacking the capacity to consent in English.
  • Those declining to participate in research will be excluded.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Heather May, Pharm.D.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions